Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression - Wikidata - awgldk - TriplyDB

Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression

Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression

http://www.wikidata.org/entity/Q35606679

about

Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature Recent updates of precision therapy for gastric cancer: Towards optimal tailored management Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?Phosphorylation by mTORC1 stablizes Skp2 and regulates its oncogenic function in gastric cancer Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.Progression inference for somatic mutations in cancer.Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation.PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer.

P2860

Q26741242-D2D5A971-0322-4F48-95AD-116F24F9B7B4 Q26746246-40486A6E-8F50-432D-A1AA-1CC3EFA690CC Q26775940-93860D05-9EF6-4C3D-9D7F-7909AFEC6217 Q26798420-E92917BE-7DF8-4D19-B2D5-0C59E7B4F78B Q28079596-8A006CAF-7441-4A51-B94E-E92D8C5C2D8B Q33608923-B383DBA6-B2FE-4770-9DB0-A2EECE886661 Q33858387-A70D4830-0217-4073-8DDA-9F294F032A47 Q36318871-D5D965A5-1B8B-4ADC-A078-6FD63B0161CA Q38793244-7E81009F-1380-4A9B-BB3B-B89741E566DE Q41050010-D6EC6EDE-4CC5-4813-AC6D-179637CB6339 Q47157362-B51D3230-6EC0-41C7-8D8C-0690A47E3E45

P2860

Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression

http://www.wikidata.org/entity/Q35606679

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Successful control of heavily ...... utation and pS6 overexpression

@ast

Successful control of heavily ...... utation and pS6 overexpression

@en

type

label

Successful control of heavily ...... utation and pS6 overexpression

@ast

Successful control of heavily ...... utation and pS6 overexpression

@en

prefLabel

Successful control of heavily ...... utation and pS6 overexpression

@ast

Successful control of heavily ...... utation and pS6 overexpression

@en

P1433

Q35606679-CAA76FCE-818B-4527-840E-A1C24FD3778A

P1476

Q35606679-21214688-1C45-4795-8CF9-3D10EBAAAB87

P2093

Q35606679-102AE76B-A3CD-4EF0-9121-82A9AE741E3A

Q35606679-1A190F01-E84A-481A-B00D-306B2F372A8C

Q35606679-5D52548F-7532-4A36-8082-52BA86814230

Q35606679-64C626C7-BFE4-4EFA-82F1-04F1C33B7EFA

Q35606679-953532E2-DD48-4348-9894-7922265881F6

Q35606679-A9BE4A58-628B-45AC-BE8B-83B1441DD47B

Q35606679-AF26398A-C779-4086-88D2-73CF27F0F92B

P2860

Q35606679-0266DD31-FC13-4178-B7D3-05B576997FCA

Q35606679-0413DE07-3210-4D37-95BD-69B5B50C2D6F

Q35606679-13BC4A1C-3BDA-4B21-86F5-F49EDC5D90B2

Q35606679-2CE77F21-86AE-4760-AE58-98C82DA8FCA4

Q35606679-331E2E11-31DB-4446-818A-589E49BF43CF

Q35606679-338B9A4A-98FA-44E2-B90B-8EA5845BE549

Q35606679-483434AC-5283-4A67-931D-A2D7FD727628

Q35606679-4D2345C3-42F3-48FD-9507-C1622DA59C5C

Q35606679-59598C9A-C876-49A6-A786-02FB2D829021

Q35606679-6DB4DA38-3872-4481-AE84-FBD82E428F61

P2888

Q35606679-82CF4A62-9DE8-4CE5-9E5F-DEBB5805510F

P304

Q35606679-CE43D254-6C17-4602-9DEE-42828FFF178B

P31

Q35606679-2ae498f4-9bb4-4657-b375-8f9c971ef3a6

Q35606679-30ABC4E4-83D5-4F3A-8A60-8DAD7B63476A

P356

Q35606679-7884842F-C278-40E3-9170-0E68A2469824

P407

Q35606679-48A1AC8F-AB5A-41CC-BDF2-7C9754B0E184

P478

Q35606679-58F0BC3E-D196-47C9-9CFA-702887C13110

P577

Q35606679-0C584930-6A92-4B8E-B476-48AD34EFE15E

P5875

Q35606679-C97E212C-AAFC-40EC-B83C-2C0EDDC01C1C

P6179

Q35606679-1EB5E749-A04E-416B-AB7C-79BC267FE027

P698

Q35606679-D43A2D23-B7F0-461B-88AA-CBFFE6FA3BF2

P921

Q35606679-6FC38489-5765-4F26-A452-1B9E8A76CB5E

P932

Q35606679-2AF52103-9C0F-4AD8-A340-C8A5098E16F7

P356

S12885-015-1139-7

P1433

P1476

Successful control of heavily ...... utation and pS6 overexpression

@en

P2093

Baek-Yeol Rhoo

http://www.w3.org/2001/XMLSchema#string

Ji Hyun Park

http://www.w3.org/2001/XMLSchema#string

Min-Hee Ryu

http://www.w3.org/2001/XMLSchema#string

Sook Ryun Park

http://www.w3.org/2001/XMLSchema#string

Yoon-Koo Kang

http://www.w3.org/2001/XMLSchema#string

Young Soo Park

http://www.w3.org/2001/XMLSchema#string

Young-Soon Na

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations of PIK3CA in gastric adenocarcinoma

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.

Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells.

The TOR pathway: a target for cancer therapy

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.

Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer.

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors

P2888

s12885-015-1139-7

P304

119

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-015-1139-7

http://www.w3.org/2001/XMLSchema#string

P407

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273702711

http://www.w3.org/2001/XMLSchema#string

P6179

1002963327

http://www.w3.org/2001/XMLSchema#string

P698

25886409

http://www.w3.org/2001/XMLSchema#string

P921

P932

4374284

http://www.w3.org/2001/XMLSchema#string